AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31340845 — intervention group
Group type: COMPARATOR
Intervention: 90-degree shoulder marginal endocrown
Number of subjects: 200
Study 28644243 — intervention group
Group type: EXPERIMENTAL
Intervention: MASK (room air through a tightly fitting face mask)
Number of subjects: 27
Study 28644243 — intervention group
Group type: COMPARATOR
Intervention: No‐MASK (room air without mask)
Number of subjects: 27
Study 28644243 — intervention group
Group type: COMPARATOR
Intervention: No‐MASK + O2 (10 l/min of oxygen via nasal cannula)
Number of subjects: 27
Study 27039086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions of real acupuncture)
Number of subjects: 70
Study 27039086 — intervention group
Group type: COMPARATOR
Intervention: Sham group (10 sessions using a Streitberger needle)
Number of subjects: 70
Study 27039086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 70
Study 24814691 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery alone (34 patients)
Number of subjects: 60
Study 24814691 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery combined with postoperative radiotherapy (26 patients)
Number of subjects: 60
Study 23106752 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy efforts by parents and support workers
Number of subjects: 197
Study 23106752 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental advocacy
Number of subjects: 197
Study 23106752 — intervention group
Group type: EXPERIMENTAL
Intervention: Support worker advocacy
Number of subjects: 197
Study 19411106 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS-RA patients with abnormal karyotype
Number of subjects: 301
Study 19411106 — intervention group
Group type: COMPARATOR
Intervention: Control groups (46 MDS-RA patients with normal karyotype and 207 patients with non-MDS anemia)
Number of subjects: 301
Study 17323786 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol PO (n = 10)
Number of subjects: 20
Study 17323786 — intervention group
Group type: COMPARATOR
Intervention: metoprolol tartrate 50 mg PO (n = 10)
Number of subjects: 20
Study 15481851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 1,350 mg/day
Number of subjects: 196
Study 15481851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 2,250 mg/day
Number of subjects: 196
Study 15481851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 15481851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (all doses)
Number of subjects: 196
Study 11479411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inoculation with 106 viable cells of plasmid-free human E. coli within 2 hours after birth
Number of subjects: 102
Study 11479411 — intervention group
Group type: COMPARATOR
Intervention: Heat-killed bacteria
Number of subjects: 102
Study 11479411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inoculation with 106 viable cells of plasmid-free human E. coli
Number of subjects: 102
Study 10743849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 30
Study 10743849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7826567 — intervention group
Group type: EXPERIMENTAL
Intervention: Monatepil
Number of subjects: 86
Study 7826567 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 86
Study 3262598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate (3 grams daily for 14 days)
Number of subjects: 29
Study 3262598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30126675 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 353
Study 30126675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 28961848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (960 mg twice daily)
Number of subjects: 675
Study 28961848 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m2 every 3 weeks)
Number of subjects: 675
Study 28961848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 675
Study 28961848 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 675
Study 26308048 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based dietary intervention based on the Mediterranean and Portfolio diets
Number of subjects: 42
Study 26308048 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 42
Study 23081873 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose systemic methotrexate (MTX)
Number of subjects: 73
Study 23081873 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 73
Study 21946399 — intervention group
Group type: EXPERIMENTAL
Intervention: hotpack + ultrasound + exercise
Number of subjects: 52
Study 21946399 — intervention group
Group type: EXPERIMENTAL
Intervention: hotpack + laser + exercise
Number of subjects: 52
Study 21946399 — intervention group
Group type: COMPARATOR
Intervention: hotpack + exercise
Number of subjects: 52
Study 19049696 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir DF (200/300 mg q.d.)
Number of subjects: 0
Study 19049696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.1 mg/kg/day)
Number of subjects: 0
Study 19049696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Emtricitabine/Tenofovir DF and Tacrolimus
Number of subjects: 0
Study 16971718 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 1011
Study 16971718 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 1011
Study 16971718 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy and postoperative chemotherapy
Number of subjects: 1011
Study 16971718 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy and postoperative chemotherapy
Number of subjects: 1011
Study 16971718 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1011
Study 16971718 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy adherence
Number of subjects: 1011
Study 16971718 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy adherence
Number of subjects: 1011
Study 16971718 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 1011
Study 12684151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 micro g)
Number of subjects: 60
Study 12684151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15803441 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-the-loser rule
Number of subjects: 0
Study 15803441 — intervention group
Group type: COMPARATOR
Intervention: Equal allocation
Number of subjects: 0
Study 15803441 — intervention group
Group type: COMPARATOR
Intervention: Other adaptive urn designs
Number of subjects: 0
Study 10025903 — intervention group
Group type: EXPERIMENTAL
Intervention: VIM3ARAC regimen (teniposide, ifosfamide, mitoxantrone, mitoguazone, high-dose methotrexate, high-dose cytarabine, prednisolone)
Number of subjects: 71
Study 10025903 — intervention group
Group type: EXPERIMENTAL
Intervention: VIM3ARAC regimen followed by stem-cell transplantation (SCT)
Number of subjects: 71
Study 10025903 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT (36 patients underwent SCT: 3 allogeneic, 33 autologous)
Number of subjects: 71
Study 10025903 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival after treatment
Number of subjects: 71
Study 10025903 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse off therapy and performance status <2 at relapse
Number of subjects: 71
Study 8749083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral acceleration steps of 0.05 g, 0.1 g, 0.24 g of 600 ms duration
Number of subjects: 6
Study 8749083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuing moving targets at similar distances and accelerations
Number of subjects: 6
Study 2375136 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg QS liquid
Number of subjects: 13
Study 2375136 — intervention group
Group type: EXPERIMENTAL
Intervention: two 200 mg QS tablets
Number of subjects: 13
Study 2375136 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg QP liquid
Number of subjects: 13
Study 2375136 — intervention group
Group type: EXPERIMENTAL
Intervention: two 275 mg QP tablets
Number of subjects: 13
Study 6448618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0
Study 6448618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31976639 — intervention group
Group type: EXPERIMENTAL
Intervention: modified group‐based high intensity aerobic interval training (m‐Ullevaal)
Number of subjects: 120
Study 31976639 — intervention group
Group type: COMPARATOR
Intervention: moderate‐intensity continuous training (MICT)
Number of subjects: 120
Study 30805908 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal biofeedback device (RegMatEx)
Number of subjects: 1015
Study 30805908 — intervention group
Group type: COMPARATOR
Intervention: Placebo biofeedback
Number of subjects: 1015
Study 28314093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic (PGx)‐guided treatment
Number of subjects: 237
Study 28314093 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care
Number of subjects: 237
Study 25675201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 20
Study 25675201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23401486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Physical Activity (SUS-PA)
Number of subjects: 170
Study 23401486 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsustained Physical Activity (UNSUS-PA)
Number of subjects: 170
Study 23401486 — intervention group
Group type: COMPARATOR
Intervention: LO-PA (Low Physical Activity)
Number of subjects: 170
Study 21323031 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenneth Reed technique
Number of subjects: 60
Study 21323031 — intervention group
Group type: COMPARATOR
Intervention: Gow-Gates technique
Number of subjects: 60
Study 18937820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild laser treatment
Number of subjects: 135
Study 18937820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 17471598 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 4
Study 17471598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 15149424 — intervention group
Group type: EXPERIMENTAL
Intervention: Long QT syndrome (LQT1, LQT2, LQT3)
Number of subjects: 0
Study 15149424 — intervention group
Group type: EXPERIMENTAL
Intervention: LQT2 and LQT3
Number of subjects: 0
Study 15149424 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 11232948 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol
Number of subjects: 66
Study 11232948 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol plus Tamoxifen
Number of subjects: 66
Study 9528198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.15%
Number of subjects: 20
Study 9528198 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.15%
Number of subjects: 20
Study 7874855 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ms neck suction (-40 mmHg) to the carotid sinus region
Number of subjects: 11
Study 7874855 — intervention group
Group type: COMPARATOR
Intervention: No stimulus (anticipation control)
Number of subjects: 11
Study 7874855 — intervention group
Group type: COMPARATOR
Intervention: Loud whistle (alerting control)
Number of subjects: 11
Study 7874855 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck suction
Number of subjects: 11
Study 29661570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip exercises
Number of subjects: 40
Study 29661570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps exercises
Number of subjects: 40
Study 29661570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 40
Study 29661570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 26354729 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training (2 sessions per week for 8 weeks)
Number of subjects: 39
Study 26354729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 26291307 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic milling
Number of subjects: 54
Study 26291307 — intervention group
Group type: COMPARATOR
Intervention: Manual rasping
Number of subjects: 54
Study 23793205 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil of Cymbopogon citratus at 1.25 μL/mL concentration, applied three times a week as shampoo and twice a day as cream for 40 days.
Number of subjects: 67
Study 23793205 — intervention group
Group type: COMPARATOR
Intervention: 2% ketoconazole formulations, applied as control for 40 days.
Number of subjects: 67
Study 21435251 — intervention group
Group type: EXPERIMENTAL
Intervention: STA OP!‐protocol (training and implementation)
Number of subjects: 168
Study 21435251 — intervention group
Group type: COMPARATOR
Intervention: Control condition (general training focusing on challenging behaviour and pain)
Number of subjects: 168
Study 19017467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 156
Study 19017467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 16902744 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavyweight PP mesh (Prolene 10 x 15 cm, 1.5 g, group I, n = 232)
Number of subjects: 672
Study 16902744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed PP- and Polyglactin mesh (Vypro II, 10 x 15 cm, 0.53 g, group II, n = 217)
Number of subjects: 672
Study 16902744 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-weight titanized PP mesh (Ti-Mesh, 10 x 15 cm, 0.24 g, group III, n = 223)
Number of subjects: 672
Study 16902744 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-weight PP meshes (group I+II)
Number of subjects: 672
Study 16902744 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 672
Study 14602749 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH for 9 months
Number of subjects: 36
Study 14602749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10934182 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for four disorders in the intervention group (576 subjects) during the first year.
Number of subjects: 1121
Study 10934182 — intervention group
Group type: COMPARATOR
Intervention: Control group (545 subjects) not screened in the first year.
Number of subjects: 1121
Study 8677083 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane stripping
Number of subjects: 120
Study 8677083 — intervention group
Group type: COMPARATOR
Intervention: Control (weekly pelvic examinations only)
Number of subjects: 120
Study 1569469 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed pointing movements executed at normal speed to a small visual target with a target shifted 10 degrees in a random direction during the movement.
Number of subjects: 0
Study 4008123 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-managed self-control program (self-monitoring, peer-assisted self-control training, alcohol education)
Number of subjects: 30
Study 4008123 — intervention group
Group type: COMPARATOR
Intervention: Minimal program intervention
Number of subjects: 30
Study 4008123 — intervention group
Group type: COMPARATOR
Intervention: Full program intervention
Number of subjects: 30
Study 28001016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) before breakfast for 90 days
Number of subjects: 24
Study 28001016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27514368 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 Day Physical Activity Recall Questionnaire (7D‐PAR)
Number of subjects: 215
Study 27514368 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer
Number of subjects: 215
Study 27514368 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 215
Study 24714415 — intervention group
Group type: EXPERIMENTAL
Intervention: AST‐120 plus once‐monthly administration of continuous EPO receptor activator (CERA)
Number of subjects: 51
Study 24714415 — intervention group
Group type: COMPARATOR
Intervention: CERA alone
Number of subjects: 51
Study 22390992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pajunk echogenic needle
Number of subjects: 144
Study 22390992 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun echogenic needle
Number of subjects: 144
Study 22390992 — intervention group
Group type: COMPARATOR
Intervention: Braun standard needle
Number of subjects: 144
Study 20369705 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianlie Jiedu Capsule + Rufloxacin
Number of subjects: 80
Study 20369705 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Rufloxacin
Number of subjects: 80
Study 19080291 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aspiration of subglottic secretions (CASS)
Number of subjects: 101
Study 19080291 — intervention group
Group type: COMPARATOR
Intervention: No aspiration of subglottic secretions (NASS)
Number of subjects: 101
Study 19080291 — intervention group
Group type: EXPERIMENTAL
Intervention: CASS
Number of subjects: 101
Study 19080291 — intervention group
Group type: COMPARATOR
Intervention: NASS
Number of subjects: 101
Study 19080291 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed early aspiration (volume of first daily aspirated secretions ≤ 20 ml)
Number of subjects: 101
Study 19080291 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with VAP
Number of subjects: 101
Study 15687530 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 397
Study 15687530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 11826413 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 91
Study 11826413 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (propranolol + isosorbide‐5‐mononitrate)
Number of subjects: 91
Study 11826413 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 91
Study 10463324 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (5 mg orally)
Number of subjects: 12
Study 10463324 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (5-HT receptor antagonist)
Number of subjects: 12
Study 10463324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7547098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium 40 mg
Number of subjects: 24
Study 7547098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg
Number of subjects: 24
Study 7547098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2170088 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 54
Study 2170088 — intervention group
Group type: COMPARATOR
Intervention: Urine glucose testing
Number of subjects: 54
Study 7022736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate (4 mg)
Number of subjects: 8
Study 7022736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine methonitrate (2 mg)
Number of subjects: 8
Study 7022736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 μg)
Number of subjects: 8
Study 7022736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atropine methonitrate with fenoterol
Number of subjects: 8
Study 7022736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atropine sulphate with fenoterol
Number of subjects: 8
Study 7022736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29781725 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded cognitive stimulation therapy (CST) model combined with tai chi, 14 sessions, twice a week
Number of subjects: 101
Study 29781725 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group received treatment as usual initially and expanded CST model later
Number of subjects: 101
Study 28629222 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Self-Efficacy (PSE)
Number of subjects: 301
Study 28629222 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Self-Efficacy (PSE) - Diet Factor
Number of subjects: 301
Study 27055107 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice plus Coenzyme Q10
Number of subjects: 40
Study 27055107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24854611 — intervention group
Group type: EXPERIMENTAL
Intervention: Early refeeding (once bowel sounds returned)
Number of subjects: 72
Study 24854611 — intervention group
Group type: COMPARATOR
Intervention: Immediately full caloric diet
Number of subjects: 72
Study 24854611 — intervention group
Group type: COMPARATOR
Intervention: Stepwise increasing diet
Number of subjects: 72
Study 24854611 — intervention group
Group type: COMPARATOR
Intervention: Early refeeding
Number of subjects: 72
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus (HSV‐1, 4.2%; HSV‐2, 98.2%) detected in genital ulcers
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial pathogens detected in genital ulcers
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV, HSV‐2, and treponemal antibodies detected
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral infections diagnosed
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: M. genitalium infections
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: T. vaginalis infections
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: C. trachomatis infections
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: N. gonorrhoeae infections
Number of subjects: 615
Study 23064538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysuria reported
Number of subjects: 615